These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26107791)

  • 1. What new therapeutic options exist for the relief of menopausal symptoms?
    Raney EC
    JAAPA; 2015 Jul; 28(7):14-6. PubMed ID: 26107791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV; Stanczyk FZ
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():93-100. PubMed ID: 30509754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
    Pinkerton JV; Conner EA
    Climacteric; 2019 Apr; 22(2):140-147. PubMed ID: 30895900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone Therapy and Other Treatments for Symptoms of Menopause.
    Hill DA; Crider M; Hill SR
    Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.
    Alvisi S; Baldassarre M; Gava G; Mancini I; Gagliardi M; Seracchioli R; Meriggiola MC
    J Sex Med; 2018 Dec; 15(12):1776-1784. PubMed ID: 30446472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
    Nappi RE; Murina F; Perrone G; Villa P; Biglia N
    Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():86-92. PubMed ID: 30509753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS; Mirkin S; Jenkins SN
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.